Cipla Ltd.

Cipla’s wholly owned subsidiary Meditab Specialities (MSPL) has acquired 75% stake in Mabpharm. The company was earlier holding 25% stake in Mabpharm. Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100% subsidiary of the company.

Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases. While, Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.